Reviewing Sera Prognostics (SERA) and Its Peers

Sera Prognostics (NASDAQ:SERAGet Rating) is one of 45 publicly-traded companies in the “Medical laboratories” industry, but how does it weigh in compared to its peers? We will compare Sera Prognostics to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, risk, profitability, dividends and earnings.


This table compares Sera Prognostics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sera Prognostics -38,185.05% -58.37% -30.80%
Sera Prognostics Competitors -1,688.14% -38.97% -18.30%

Insider & Institutional Ownership

63.2% of Sera Prognostics shares are owned by institutional investors. Comparatively, 61.6% of shares of all “Medical laboratories” companies are owned by institutional investors. 11.6% of Sera Prognostics shares are owned by insiders. Comparatively, 18.2% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Sera Prognostics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sera Prognostics 0 1 4 0 2.80
Sera Prognostics Competitors 356 1109 1767 47 2.46

Sera Prognostics presently has a consensus target price of $18.50, indicating a potential upside of 1,323.08%. As a group, “Medical laboratories” companies have a potential upside of 105.49%. Given Sera Prognostics’ stronger consensus rating and higher possible upside, analysts clearly believe Sera Prognostics is more favorable than its peers.

Valuation and Earnings

This table compares Sera Prognostics and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Sera Prognostics $80,000.00 -$35.01 million -0.30
Sera Prognostics Competitors $1.09 billion $56.72 million 8.82

Sera Prognostics’ peers have higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


Sera Prognostics peers beat Sera Prognostics on 8 of the 12 factors compared.

About Sera Prognostics (Get Rating)

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Want More Great Investing Ideas?

Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with's FREE daily email newsletter.